Pegylated interleukin-2 - PharmaEssentia Corporation
Alternative Names: P-11838Latest Information Update: 01 Jan 2026
At a glance
- Originator PharmaEssentia Corporation
- Class Anti-inflammatories; Interleukins
- Mechanism of Action Interleukin 2 replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Immunological disorders; Inflammation